Silkworm Pupa Powder Improves Alzheimer's Disease

Inclusion Criteria: * Diagnosis of probable Alzheimer's disease (AD) according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria. Disease severity is classified as mild to moderate, defined as a Mini-Mental State Examination (MMSE) total score of 0-24 points, inclusive, at both screening and baseline. * Confirmation of AD pathology per the 2024 revised AD diagnostic criteria (biomarker-defined AD with both Aβ and tau positivity): * Aβ positivity: Plasma Aβ42/40 ratio ≤0.08 or amyloid-PET positivity (SUVR ≥1.1). * Tau positivity: Plasma p-tau217 ≥2.5 pg/mL (or CSF p-tau181/Aβ42 ratio ≥0.02). * Age 50 to 90 years (inclusive), male or female, with at least a primary school education. * Stable medication use: If receiving approved AD therapies (e.g., acetylcholinesterase inhibitors, GV-971, NMDA receptor antagonists), doses must remain stable for ≥12 weeks prior to baseline. Treatment-naïve participants are also eligible. All other permitted non-AD related concomitant medications must remain stable for ≥4 weeks prior to baseline unless otherwise specified. * Hachinski Ischemia Scale (HIS) total score ≤4. * Geriatric Depression Scale-15 (GDS-15) total score ≤4. * Neuroimaging evidence: Screening CT/MRI showing age-related brain changes or cerebral atrophy. * Participant has a stable and reliable caregiver, as confirmed by the investigator. * Written informed consent must be provided by the participant or, if the participant lacks decision-making capacit…